Product Description
Mechanisms of Action: ADORA1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Solvay Pharm
Company Location: 1120 BRUSSELS C9 00000
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Heart Failure|Heart Failure, Acute|Acute Kidney Injury|Kidney Diseases|Heart Failure, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| S320.2.003 | N/A |
Terminated |
Heart Failure|Kidney Diseases |
2008-11-01 |
2019-03-22 |
Treatments |
|
| 2008-003786-20 | P2 |
Terminated |
Heart Failure, Acute |
2010-01-04 |
2022-03-12 |
Treatments |
|
| Reno-Defend 1 | P2 |
Terminated |
Heart Failure, Acute|Kidney Diseases|Acute Kidney Injury |
2010-01-01 |
2019-03-18 |
||
| 2007-000490-40 | P2 |
Completed |
Kidney Diseases|Heart Failure, Chronic |
2009-03-20 |
2022-03-12 |
||
| 2004-000442-21 | P2 |
Completed |
Heart Failure, Chronic |
2008-02-04 |
2022-03-12 |
Treatments |
|
| S320.2.002 | P2 |
Completed |
Heart Failure |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|